Literature DB >> 8528199

WASP gene mutations in Wiskott-Aldrich syndrome and X-linked thrombocytopenia.

J M Derry1, J A Kerns, K I Weinberg, H D Ochs, V Volpini, X Estivill, A P Walker, U Francke.   

Abstract

The WASP gene has been recently cloned from Xp11.23 and shown to be mutated in three patients with the Wiskott-Aldrich syndrome (WAS). We have developed a screening protocol for identifying WASP gene alterations in genomic DNA and have identified a spectrum of novel mutations in 12 additional unrelated families. These missense, nonsense and frameshift mutations involve eight of the 12 exons of the gene. Two mutations creating premature termination codons were associated with lack of detectable mRNA on Northern blots. Four amino acid substitutions, Leu27Phe, Thr48Ile, Val75Met and Arg477Lys, were found in patients with congenital thrombocytopenia and no clinically evident immune defect indicating that the WASP gene is the site for mutations in X-linked thrombocytopenia as well as in WAS. A T-cell line from a WAS patient contained two independent DNA alterations, a constitutional frameshift mutation, also present in peripheral blood leukocytes from the patient, and compensatory splice site mutation unique to the cell line. The distribution of eight missense mutations provides valuable information on amino acids which are essential for normal protein function, and suggests that sites in the first two exons are hot-spots for mutation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8528199     DOI: 10.1093/hmg/4.7.1127

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  23 in total

Review 1.  The Wiskott-Aldrich syndrome.

Authors:  H D Ochs
Journal:  Clin Rev Allergy Immunol       Date:  2001-02       Impact factor: 8.667

Review 2.  RNA interference: a potent technology in studying and modulating of dendritic cells, and potential in clinical therapy.

Authors:  Fang Cheng; Song He
Journal:  Mol Biol Rep       Date:  2009-09-12       Impact factor: 2.316

Review 3.  The Wiskott-Aldrich syndrome.

Authors:  H D Ochs
Journal:  Springer Semin Immunopathol       Date:  1998

4.  2012 William Allan Award: Adventures in cytogenetics.

Authors:  Uta Francke
Journal:  Am J Hum Genet       Date:  2013-03-07       Impact factor: 11.025

5.  WASP-interacting protein is important for actin filament elongation and prompt pseudopod formation in response to a dynamic chemoattractant gradient.

Authors:  Scott A Myers; Laura R Leeper; Chang Y Chung
Journal:  Mol Biol Cell       Date:  2006-08-09       Impact factor: 4.138

6.  Role and structural mechanism of WASP-triggered conformational changes in branched actin filament nucleation by Arp2/3 complex.

Authors:  Max Rodnick-Smith; Qing Luan; Su-Ling Liu; Brad J Nolen
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-20       Impact factor: 11.205

7.  N-WASP, a novel actin-depolymerizing protein, regulates the cortical cytoskeletal rearrangement in a PIP2-dependent manner downstream of tyrosine kinases.

Authors:  H Miki; K Miura; T Takenawa
Journal:  EMBO J       Date:  1996-10-01       Impact factor: 11.598

8.  Studies of the expression of the Wiskott-Aldrich syndrome protein.

Authors:  D M Stewart; S Treiber-Held; C C Kurman; F Facchetti; L D Notarangelo; D L Nelson
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

9.  NMR determines transient structure and dynamics in the disordered C-terminal domain of WASp interacting protein.

Authors:  Noam Y Haba; Renana Gross; Jiri Novacek; Hadassa Shaked; Lukas Zidek; Mira Barda-Saad; Jordan H Chill
Journal:  Biophys J       Date:  2013-07-16       Impact factor: 4.033

10.  Mutations in Drosophila enabled and rescue by human vasodilator-stimulated phosphoprotein (VASP) indicate important functional roles for Ena/VASP homology domain 1 (EVH1) and EVH2 domains.

Authors:  S M Ahern-Djamali; A R Comer; C Bachmann; A S Kastenmeier; S K Reddy; M C Beckerle; U Walter; F M Hoffmann
Journal:  Mol Biol Cell       Date:  1998-08       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.